TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the best cheap biotech stocks to buy now. TG Therapeutics, Inc. (NASDAQ:TGTX) released financial results for fiscal Q4 and full year 2025 on February 26. It reported fiscal Q4 and full year 2025 total revenue of $192.6 million and $616.3 million, respectively, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively. U.S. net product revenue for BRIUMVI reached $182.7 million for fiscal Q4 2025, reflecting around 20% quarterly growt ...